Any current/future capex/capital investment/strategic investment?

Opening 29 new branch offices across India in FY 2023-24, with an estimated investment of around Rs. 3.2 crore; branches expected to break even in 1.5 to 2 years. (Page 16-17) Investments in digital strategy: expanding a 14-member digital team, hiring data analysts, and upgrading digital and IT assets to enhance investor engagement via apps and websites. (Page 18) Significant investments in building capabilities and infrastructure for investment teams, including customized training and development programs. (Page 4) UTI Capital is building alternative investment products with plans to launc

Future growth expectations in sales/revenue/volumes?

Focus on improving fund performance to drive inflows and market share, especially in equity funds. Strategic launch of a BAF product pending SEBI approval to boost fundraising. Continuous engagement with distributors, including banking channels, to promote products. Expansion plans include opening 29 new branches targeting Tier 3 and Tier 4 cities with a break-even expected in 1.5-2 years. Digital strategy enhancement with hiring of data analysts and improving digital platforms to engage young investors. Staff cost expected to grow moderately (~3.5%) due to controlled salary increase

Future growth expectations in earnings/operating earnings/profits/EPS?

Staff costs expected to grow moderately (~3.5%) due to controlled salary hikes and retirements, aiding cost management (Page 23, 22). Non-staff costs to have limited increase; one-time expenses (e.g., sales meet) removed, but CSR and renovation costs may add (Page 23). Focus on cost optimization is expected to keep administrative expenses stable without significant rise (Page 23). Overall expense growth targeted to improve beyond past 6% rate through initiatives and cost discipline (Page 23). Income growth supported by increased payout ratio (raised from 48% in FY21 to 63% in FY22), expected t

UTI AMCQ4 FY23Capital Markets

UTI AMC Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹842.2P/E: 18.0Market Cap: ₹10.8K CrSector: Capital Markets

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Focus on improving fund performance to drive inflows and market share, especially in equity funds.
Strategic launch of a BAF product pending SEBI approval to boost fundraising.
Continuous engagement with distributors, including banking channels, to promote products.
Expansion plans include opening 29 new branches targeting Tier 3 and Tier 4 cities with a break-even expected in 1.5-2 years.
Digital strategy enhancement with hiring of data analysts and improving digital platforms to engage young investors.
Staff cost expected to grow moderately (~3.5%) due to controlled salary increases and retirements.
Payout ratio increased from 48% to 63% in FY22, expected to be maintained or improved, subject to board decisions.
Expectation to stabilize or improve yields with a focus on new AUM and managing competitive dynamics.
Overall aim to regain and grow market share through performance, distribution expansion, and digital initiatives.

Margin guidance

Category 3

Staff costs expected to grow moderately (~3.5%) due to controlled salary hikes and retirements, aiding cost management (Page 23, 22).
Non-staff costs to have limited increase; one-time expenses (e.g., sales meet) removed, but CSR and renovation costs may add (Page 23).
Focus on cost optimization is expected to keep administrative expenses stable without significant rise (Page 23).
Overall expense growth targeted to improve beyond past 6% rate through initiatives and cost discipline (Page 23).
Income growth supported by increased payout ratio (raised from 48% in FY21 to 63% in FY22), expected to be maintained or improved (Page 26).
Business expansion, including digital and physical branches, aims for medium-term profitability improvements (branches expected to break-even in 1.5-2 years) (Page 17,16).
Stable equity yields anticipated with a largely new AUM book, contributing to stabilized operating earnings (Page 15).

See what UTI AMC management said on margin guidance — free account, 30 seconds.

Fundraise plans

- UTI Capital Pvt. Ltd. is building its business and managing several active debt funds with current fundraisings: - UTI Structured Debt Opportunities Fund (SDOF) III launched in September 2022, currently in fundraising and investing stage with AUM Rs. 300 crore. - For UTI International, there are plans for new fund launches in the U.S. market; legal and registration expenses are expected but precise costs are not finalized. - No direct equity New Fund Offers (NFOs) launched in FY23, but several ETFs and fund of funds were introduced. - Approval for launching a Balanced Advantage Fund (BAF) is awaited from SEBI, which is strategized to aid future fundraising. - The company is focusing on expanding geographical reach and digital presence to support product sales and fund inflows. Thus, active new fundraising is ongoing primarily through debt-focused products at UTI Capital and planned product launches internationally and in hybrid categories post regulatory approval.

Order book

The provided pages from the document "1274795.pdf" do not contain specific information on the current or expected order book or pending orders. The discussions primarily focus on: - Fund performance, sales strategy, and market share in equity and hybrid funds. - Dividend payout ratios and their maintenance or increase. - Expense outlook including staff cost growth. - Digital strategy and branch expansion plans. - Competitive dynamics in distributor commissions and product positioning. - Fund inflows, yields, and distributions across channels. - Launch of new products, including Balanced Advantage Fund (BAF) awaiting regulatory approval. - International business expense considerations related to UTI International. No explicit details on order book, pending orders, or similar order-related metrics are mentioned in these excerpts.

See what UTI AMC management said on order book — free account, 30 seconds.

Capex plans

Yes

Opening 29 new branch offices across India in FY 2023-24, with an estimated investment of around Rs. 3.2 crore; branches expected to break even in 1.5 to 2 years. (Page 16-17)
Investments in digital strategy: expanding a 14-member digital team, hiring data analysts, and upgrading digital and IT assets to enhance investor engagement via apps and websites. (Page 18)
Significant investments in building capabilities and infrastructure for investment teams, including customized training and development programs. (Page 4)
UTI Capital is building alternative investment products with plans to launch funds such as Real Estate Opportunities Fund; has made net loss of Rs. 3.3 crore due to investments to build this business. (Page 5, 9)
UTI International expanding operations with new subsidiary UTI Investments America for North American market; incurring legal and registration expenses for new fund launches. (Page 21, 9)
Past significant investments in IT infrastructure and security, with reduced IT investments expected going forward. (Page 23)

Track UTI AMC — get its next earnings analysis in your feed

How does UTI AMC rank vs peers in Capital Markets?

Pro feature

ThisUTI AMC

Rev 3Mar 3

See where UTI AMC sits in Capital MarketsSee which companies these are, and every other name in the sector.Open rankings

How does UTI AMC rank in Capital Markets?

Compare UTI AMC against every Capital Markets company (Q4 FY23) on revenue, margins and earnings-call signals.

View Capital Markets leaderboard →

What UTI AMC's management said in earlier quarters

Earlier calls (8)

Others in Capital Markets this season

Systematix Corporate Services (Q2 FY27)
Q2 FY27 total revenue from operations (consolidated): ₹57.81 Cr, up 0.50% YoY vs. Key investor presentation takeaways from Systematix Corporate Services Ltd's Q
Indo Thai Securities (Q2 FY27)
Q2 FY27 revenue excluding fair value changes: ₹7.56 Cr, up 18.7% year-on-year (Page 13) . Key investor presentation takeaways from Indo Thai Securities Ltd's Q2
Gretex Corporate (Q2 FY27)
H1 FY27 saw an 11.4% year-on-year revenue growth, indicating positive momentum. Key concall takeaways from Gretex Corporate Services Ltd's Q2 FY27 earnings…
Nuvama Wealth (Q2 FY27)
Wealth and Private Wealth businesses have consistently compounded >20% growth over the last three years. Key concall takeaways from Nuvama Wealth Management…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

UTI AMC Q4 FY23 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does UTI AMC rank in Capital Markets?

Continue your research

What UTI AMC's management said in earlier quarters

Others in Capital Markets this season